I’m still extremely bullish on the big numbers. The prospects of a blockbuster buyout (anything in excess of $50 per share in my opinion) are tied to comprehensive data. That data needs to demonstrate wide application, improvement in combination - and a worldwide addressable market that proves the dosage demands and value per patient.
I truly think (and always have) that bisantrene will prove to be the next Keytruda.
DT and the BOD are working towards as much valuable and broad data as possible - as quickly as possible.
Gun to my head, I think we should achieve US$13-21bn or more - or about 2-4x the conservative Triangle Report, if we have the data to back it up. This would still be a bargain for BP even at the top end of that price range.
General Comments / Chat, page-9992
-
- There are more pages in this discussion • 1,372 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.050(3.03%) |
Mkt cap ! $289.6M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.70 | $1.63 | $181.9K | 109.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11946 | $1.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.75 | 27579 | 4 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |